Abstract
INTRODUCTION
Epidermal growth factor receptor (EGFR) gene mutation is detected in 30-40% of lung adenocarcinoma and associated with specific demographic parameters such as never-smoker, Asian and female gender [1] [2] [3] . EGFR gene mutation is the most important molecular target, and tyrosine kinase inhibitors (TKIs) targeting EGFR gene mutation have been shown to significantly improve the prognosis of advanced lung adenocarcinoma [4] [5] [6] . Post-recurrence survival of lung adenocarcinoma patients with EGFR gene mutation has also been improved by the use of TKIs [7, 8] . It is evident that EGFR gene mutation is a predictive factor in the treatment of lung adenocarcinoma. However, the prognostic effect of EGFR gene mutation on tumour progression, which affects recurrence pattern and dynamics, has not been well established [9] . Several prospective studies have reported that lung adenocarcinoma with EGFR gene mutation had longer progression intervals than those with wild-type EGFR gene in chemotherapy-alone subgroups [2, 10] . As low-dose computed tomography screening becomes more popular [11, 12] , the number of detected early adenocarcinomas and the number of surgically treated lung adenocarcinoma will also increase. Therefore, understanding the prognostic characteristics of adenocarcinoma with EGFR gene mutation is important for predicting accurate prognosis and for customizing the surveillance programme for patients with completely resected lung adenocarcinoma. In this study, the relationship between EGFR gene mutations and the recurrence dynamics of completely resected lung adenocarcinoma was investigated.
MATERIALS AND METHODS

Study population
A total of 527 patients who underwent curative surgery for lung adenocarcinoma from January 2006 to December 2009 were reviewed retrospectively. The data for age, sex, histological subtype, presence of EGFR mutation, extent of pulmonary resection, pathological stage (7th edition of Lung cancer stage classification system) [13] , adjuvant treatment, recurrence status, first recurrence site, disease-free interval (DFI), survival status and survival duration were obtained by reviewing medical records. DFI was defined as months from the day of operation to the day of clinical or radiological detection of recurrence. The survival duration was counted from the day of surgery to the day of death by any causes or the day of last follow-up in months. Platinum-based cytotoxic chemotherapy was standard adjuvant treatment in patients with pathological stage II disease or more. No adjuvant TKI treatment was performed in the present study. Postoperative surveillance of recurrence was conducted by contrast-enhanced chest computed tomography (CT) every 6 months for 2 years, and then chest low-dose CT was performed annually. Positron emission tomography-CT was performed case by case. Histological confirmation of recurrence was performed in patients with ambiguous image findings on CT or positron emission tomography-CT. Recurrence and second primary lung cancer were classified according to the Martini and Melamed classification [14] and criteria proposal by International Association for the Study of Lung Cancer [15] . Types of recurrences were classified into loco-regional recurrence (recurrences at resection margin or N1/N2 nodes) or distant metastasis (ipsilateral lung, ipsilateral pleural space, contralateral intrathoracic metastasis, extrathoracic metastasis). Histological subtype was determined according to the International Association for the study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma [16] . Tumours were graded according to the dominant subtype: Low grade-adenocarcinoma in situ and minimally invasive adenocarcinoma; Moderate grade-lepidic, acinar and papillary subtypes; High grade-solid and micropapillary subtypes [17] . The last follow-up date was 30 June 2016. Invasive mucinous adenocarcinomas, pathological stage IV and operative mortality cases were excluded.
Epidermal growth factor receptor gene mutation test EGFR gene mutation was tested by nested polymerase chain reaction followed by bidirectional direct sequencing in the event of recurrence [7] . EGFR gene expression was also tested in some patients by immunohistochemistry during the early period of this study. The results of immunohistochemistry for EGFR gene mutation were excluded from the analyses.
Statistical analyses
Adenocarcinoma patients who experienced recurrence and had been tested for EGFR gene mutation by direct sequencing were included in the analyses. Patients were classified according to whether their adenocarcinoma had EGFR gene mutation (M group) or wild-type EGFR genes (W group) (Fig. 1) . Recurrence sites and DFIs of the 2 groups were compared. T-test was used for the comparison of continuous variables, and chi-square method was used for the comparison of discrete variables. DFI and overall survival rate were calculated using the KaplanMeier method and compared using the log-rank test for univariable analysis. Prognostic effects of age (< _60 vs >60), sex, smoking status (<30 pack-year vs > _30 pack-year), histological grade, pathological stage (I vs II + III), extent of surgery (lobectomy versus bilobectomy + pneumonectomy), visceral pleural invasion, lymphovascular invasion, adjuvant treatment and EFGR gene mutation on DFI were tested. Parameters showing P-value 0.1 or less in univariable analysis were included in multivariable analysis conducted according to Cox's proportional hazard model. P-values <0.05 were considered statistically significant. Statistical analyses were performed using the Statistical Package for Social Science (ver. 21.0, IBM Corp., Armonk, NY, USA). This study was approved by the Institutional Review Board of Seoul National University Hospital (approval number: H-1506-018-678), and it complied with the Declaration of Helsinki.
RESULTS
A total of 527 patients with a mean age of 62.5±10 years (range: 23-83 years) had adenocarcinoma, of whom 282 (53.5%) were female. There were 351 (66.6%) patients with stage I, 69 (13.1%) with stage II and 107 (20.3%) with stage III adenocarcinoma. The median follow-up duration was 72 months. The 5-year overall survival rate was 80.1%. Recurrence was detected in 149 patients, and the 5-year disease-free survival (DFS) rate was 60.5%. Initial recurrences of 7 (1.3%) patients were loco-regional recurrences (resection margin-3, N2 node-4), and 142 (26.9%) patients presented with distant metastases (ipsilateral lung-18, ipsilateral pleural seeding-17, others-107). Twenty-four (4.6%) patients underwent additional surgery for second primary lung cancer during the study period. Pathological stage was the only prognostic factor for recurrence (I vs II/III, P = 0.03). EGFR gene mutation test by the direct sequencing method was performed in 115 (77.2%) patients with recurrent adenocarcinoma. Reasons for excluding 34 (22.8%) patients were (i) EGFR gene mutation test was done only by immunohistochemistry and (ii) no EGFR gene mutation test was performed due to omission of subsequent TKI treatment because of impaired performance status or refusal of treatment.
Recurrent adenocarcinoma with epidermal growth factor receptor gene sequencing Table 1 lists the demographics and pathological characteristics of the study population. The mean age was 64 ± 10 (range: 34-83), and 59 (50%) patients were female. The median DFI was 19.0 [95% confidence interval (CI) = 16.6-21.3] months. There were 6 (5.2%) loco-regional recurrences (resection margin-2, N2 nodes-4) and 109 (94.8%) distant metastases (ipsilateral lung-17, ipsilateral pleural seeding-13, others-79). EGFR gene mutations were detected in 66 (57.4%) patients, and 49 (42.6%) patients had wild-type EGFR genes. EGFR gene mutations were found at exon 18 in 2 (3%) patients, exon 19 in 37 (56.1%) patients, exon 20 in 5 (7.6%) patients, exon 21 in 21 (31.8%) patients and exon 22 in 1 (1.5%) patient. No recurrence occurred in patients with low-grade histology. The proportion of females was higher in the M group, and the proportion of heavy smokers was higher in the W group. There was no difference in age, pathological stage, extent of resection and adjuvant treatment between M and W groups ( Table 2 ). Types of recurrence in the M group were loco-regional in 4 (6.1%) patients and distant metastasis in 62 (93.9%) patients. The types of recurrence in the W group were loco-regional in 2 (4.1%) patients and distant metastasis in 47 (95.9%) patients. The types of recurrence were not significantly different between the 2 groups (P = 0.50). However, the median DFI of the 2 groups were significantly different (M group: 20.3 months, W group: 15.1 month, P = 0.012) (Fig. 2) . Univariable analyses showed that EGFR gene mutation was the only prognostic factor for DFI. Sex, age, smoking history, histological grade, pathological stage, visceral pleural invasion, lymphovascular invasion, extent of resection and adjuvant treatment were not prognostic factors for DFI (Table 3 ). Multivariable analysis showed that EGFR gene mutation [hazard ratio (HR) = 0.639, 95% CI = 0.428-0.954, P = 0.029] was the only prognostic factor for DFI (Table 4 ). Subgroup analyses of patients with distant metastasis showed similar results. The median DFI of the M group was significantly longer than that of the W group (M group: 20.3 months, W group: 14.6 months, P = 0.002). EGFR gene mutation (HR = 0.534, 95% CI = 0.339-0.839, P = 0.007) was the only significant prognostic factor for DFI of distant metastasis in univariable and multivariable analyses. 
DISCUSSION
This study found that lung adenocarcinomas with an EGFR gene mutation progress more slowly than those with a wild-type EGFR gene. The difference was more pronounced in distant metastasis. DFI was significantly longer in the EGFR gene mutation group than in the wild-type EGFR gene group by about 5 months in all recurrence and about 6 months in distant metastasis. This finding suggests that the recurrence dynamics of adenocarcinoma differ according to whether EGFR gene mutation had occurred and that the prognosis of adenocarcinoma with EGFR gene mutation is better than that with wild-type EGFR gene. The predictive effect of EGFR gene mutation has been investigated extensively in lung adenocarcinoma because it is a promising target for TKI treatment [4] [5] [6] [7] [8] . In contrast, the prognostic effect of EGFR gene mutation has received less attention, and the findings regarding the prognostic effect of EGFR gene mutation have been controversial. Several prospective studies revealed a favourable prognostic effect of EGFR gene mutation in advanced lung adenocarcinomas. Secondary analysis of the IDEAL/INTACT trial showed that adenocarcinomas with EGFR gene mutation had a better prognosis than those with a wild-type EGFR gene in patients treated by cytotoxic chemotherapy only [10] . The TRIBUTE trial also showed that the time-to-progression of nonsmall-cell carcinoma with EGFR gene mutation was longer than that with wild-type EGFR gene in the cytotoxic chemotherapy alone group [2] . These findings suggest that adenocarcinomas with EGFR gene mutation are less aggressive and that the presence of EFGR gene mutation is a prognostic factor in lung adenocarcinoma. Retrospective studies about the prognostic effect of EGFR mutation in early lung adenocarcinoma were performed on a small number of patients because EGFR gene mutation test was not routinely performed on the completely resected early lung adenocarcinoma patients in clinical settings. Several of these retrospective studies showed similar results to those shown in the present study. Lee et al. [18] reported that the presence of wild-type EGFR gene was a risk factor for recurrence with an adjusted HR of 1.42. Marks et al. [19] reported that adenocarcinoma patients with EGFR gene mutation showed longer overall survival times compared with those with wild-type EGFR gene after adjusting for the stage (HR = 0.4) in a study that included only patients who had not received TKI treatment. Izar et al. reported that EGFR mutation was associated with a significantly lower recurrence rate than wild-type EGFR gene (mutation group: 9.7%, wild-type group: 21.6%, P = 0.03) and longer median DFS (mutation group: 8.8 years, wild-type group: 7.0 years, P = 0.0085). The presence of an EGFR mutation was an independent prognostic factor for DFS in completely resected stage I nonsmall-cell carcinoma patients in that study [20] .
However, other studies have reported opposite results. Lin et al. reported that EGFR gene mutation had no prognostic effect in resected stage I lung adenocarcinoma after analysing adenocarcinoma patients (87 with EGFR gene mutation and 33 with wild-type EGFR gene). However, considering that approximately 60% of their patients had low-grade histology, the sample size was too small to draw meaningful conclusions [21] . Ohba et al. [22] analysed 256 patients with resected pathological stage I adenocarcinoma and could not find the prognostic effect of EGFR gene mutation on DFS.
The types of recurrence were similar for adenocarcinoma with EGFR gene mutation and wild-type EGFR gene, which suggested that mode of recurrence did not differ according to EGFR gene mutation status. Most of the recurrences in the present study were distant metastasis, and a subgroup analysis with distant metastases also showed longer DFI in adenocarcinoma with EGFR gene mutation. This finding suggests that sub-clinical micrometastases of adenocarcinoma with EGFR gene mutation progress to clinically detectable metastases more slowly.
EGFR gene mutation has been shown to be associated with histological subtypes of adenocarcinoma. No EGFR gene mutation is expected in mucinous adenocarcinoma. An EGFR gene mutation is more frequent in adenocarcinoma in situ, non-mucinous lepidic predominant, papillary and micropapillary subtypes [16] . Yoshizawa et al. [17] reported that EGFR gene mutation was found more frequently in the adenocarcinomas with non-mucinous lepidic and micropapillary patterns and less frequently in those with a solid component. Similarly, Yanagawa et al. [23] found EGRF gene mutations in more than 40% of adenocarcinomas with a lepidic, acinar, papillary and micropapillary subtype and only in 28% of those with a solid subtype. A French study also reported that EGFR gene mutation was more frequent in intermediate-grade histologies than in high-grade histologies [24] . In the present study, EGFR gene mutation rates did not differ according to histological grades in recurrent lung adenocarcinoma. This result suggests that the likelihood of the presence of EGFR gene mutation is similar between histological subtypes of recurrent adenocarcinoma and that the effect of TKI treatment on recurrent adenocarcinoma would be similar for different histological subtypes.
Limitations
Limitations of this study are the small number of patients and the fact that only patients with recurrence were included. During the study period, direct sequencing of EGFR gene was usually performed in recurrent adenocarcinomas only. Therefore, the present study had to be focused on patients with recurrence. Although it could not show the whole picture of the recurrence dynamics of completely resected lung adenocarcinoma, the present study did reflect the recurrence dynamics of lung adenocarcinoma with micrometastases at the time of surgery because the follow-up duration was long enough to detect any possible recurrences and the presence of EGFR gene mutation was tested with a reliable method. Further study with a prospective cohort of resected lung adenocarcinoma with EGFR gene mutation test is required to verify the results of this small study. We have begun collecting such data for a study in the future.
CONCLUSION
In conclusion, lung adenocarcinoma with EGFR gene mutation was shown to have longer progression intervals and less aggressive recurrence dynamics than that with wild-type EGFR gene, especially with regard to distant metastasis. This finding should be considered in the conduct of postoperative surveillance of completely resected lung adenocarcinomas. The mechanism controlling the slow progression of distant metastasis in the lung adenocarcinoma with EGFR gene mutation should be investigated.
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